Mary Barrett

Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven

Gerhardt Attard, Alison Reid, Timothy A. Yap et al. · Journal of Clinical Oncology · 2008 · 896 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers

Ruth Plummer, Gerhardt Attard, Simon Pacey et al. · Clinical Cancer Research · 2007 · 245 citations · Full text

Medicine, Oncology, Pharmacology +17

Clinical experience of marketed Levetiracetam in an epilepsy clinic—a one year follow up study

Tim Betts, HELEN YARROW, Lyn Greenhill et al. · Seizure · 2003 · 48 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +9

Phase I study of continuous oral dosing of an irreversible CYP17 inhibitor, abiraterone (A), in castration refractory prostate cancer (CRPC) patients (p) incorporating the evaluation of androgens and steroid metabolites in plasma and tumor

Gerhardt Attard, Timothy A. Yap, Alison Reid et al. · Journal of Clinical Oncology · 2007 · 17 citations

Medicine, Endocrinology, Pharmacology +17